LLBH Private Wealth Management LLC acquired a new position in shares of Pfizer, Inc. (NYSE:PFE) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 28,900 shares of the biopharmaceutical company’s stock, valued at approximately $971,000.

Several other large investors also recently bought and sold shares of PFE. Alexandria Capital LLC increased its holdings in shares of Pfizer by 3.5% during the 1st quarter. Alexandria Capital LLC now owns 7,153 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 245 shares during the period. Glen Harbor Capital Management LLC increased its holdings in shares of Pfizer by 41.9% during the 1st quarter. Glen Harbor Capital Management LLC now owns 134,304 shares of the biopharmaceutical company’s stock worth $4,595,000 after purchasing an additional 39,632 shares during the period. Cubic Asset Management LLC increased its holdings in shares of Pfizer by 0.8% during the 1st quarter. Cubic Asset Management LLC now owns 174,267 shares of the biopharmaceutical company’s stock worth $5,962,000 after purchasing an additional 1,380 shares during the period. Dubuque Bank & Trust Co. increased its holdings in shares of Pfizer by 2.1% during the 1st quarter. Dubuque Bank & Trust Co. now owns 38,005 shares of the biopharmaceutical company’s stock worth $1,300,000 after purchasing an additional 768 shares during the period. Finally, Delta Asset Management LLC TN increased its holdings in shares of Pfizer by 1.7% during the 1st quarter. Delta Asset Management LLC TN now owns 44,949 shares of the biopharmaceutical company’s stock worth $1,538,000 after purchasing an additional 769 shares during the period. Institutional investors own 69.36% of the company’s stock.

In related news, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Laurie J. Olson sold 8,064 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the sale, the insider now directly owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The disclosure for this sale can be found here. Insiders have sold 374,621 shares of company stock worth $12,796,098 over the last quarter. 0.06% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/llbh-private-wealth-management-llc-buys-new-holdings-in-pfizer-inc-pfe/1713136.html.

Pfizer, Inc. (PFE) opened at $35.37 on Friday. Pfizer, Inc. has a 12-month low of $30.51 and a 12-month high of $36.78. The stock has a market cap of $210,830.20, a P/E ratio of 14.15, a PEG ratio of 2.50 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same period in the prior year, the business earned $0.61 earnings per share. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. research analysts anticipate that Pfizer, Inc. will post 2.6 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. Pfizer’s payout ratio is 79.01%.

PFE has been the topic of a number of analyst reports. BMO Capital Markets reissued a “buy” rating and issued a $37.00 target price on shares of Pfizer in a research note on Wednesday, September 6th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research note on Wednesday, September 13th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday, October 3rd. Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $35.00 to $39.00 in a research note on Wednesday, September 20th. Finally, ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. Pfizer has an average rating of “Hold” and an average price target of $38.48.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.